Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD L1 IHC Skip to main contentScroll Back to Top
Poster
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD L1 IHC
June 2, 2022